High-dose XXXX in advanced @entity135 .

@entity1 @entity135 @entity137 @entity66 @entity2167 @entity1219 @entity957 @entity900 @entity3003 @entity16
In 22 @entity1 with advanced @entity957 of the @entity135 we evaluated the efficacy and @entity137 of 200 mg/m2 @entity900 administered in 3% @entity1219 with vigorous hydration. Six @entity1 had previously untreated stage IV disease and 16 @entity1 had @entity66 , including eight with prior chemotherapy including low-dose @entity900 and @entity3003 . @entity900 was administered as a brief infusion, either 40 mg/m2/day X 5 or 50 mg/m2/day X4, every 28 days. Objective responses were observed in 16 of 22 (73%) @entity1 , including 5 of 6 (83%) previously untreated @entity1 and 11 of 16 (69%) @entity1 with @entity66 . This included two complete responses, one confirmed pathologically. Fifty-seven courses of drug were administered and @entity137 was monitored with serial creatinine clearance determinations, audiograms, and sensorimotor exams. @entity16 and @entity2167 were dose-limiting and led to the stopping of treatment in 12 of the 16 responders after one to four courses (median three courses). Only two responding @entity1 continued treatment until disease progression occurred at 3 and 4 months after achieving maximum response. Acute, transient nephrotoxicity occurred in four @entity1 ; two were retreated. Moderate myelosuppression occurred in all @entity1 but was not treatment-limiting. For most @entity1 the maximally tolerated number of courses was three. The median survival time was 33.5 weeks for @entity66 @entity1 , 108 weeks for newly diagnosed @entity1 . This regimen is not recommended for the palliation of @entity66 . However, the very high response rate suggests that high-dose @entity900 may have a useful role in induction or adjuvant chemotherapy regimens.
